Literature DB >> 15896705

2.0 A crystal structure of human ARL5-GDP3'P, a novel member of the small GTP-binding proteins.

Zhan-Xin Wang1, Liang Shi, Jun-Feng Liu, Xiao-Min An, Wen-Rui Chang, Dong-Cai Liang.   

Abstract

ARL5 is a member of ARLs, which is widespread in high eukaryotes and homologous between species. But no structure or biological function of this member is reported. We expressed, purified, and resolved the structure of human ARL5 with bound GDP3'P at 2.0 A resolution. A comparison with the known structures of ARFs shows that besides the typical features of ARFs, human ARL5 has specific features of its own. Bacterially expressed human ARL5 contains bound GDP3'P which is seldom seen in other structures. The hydrophobic tail of the introduced detergent Triton X-305 binds at the possible myristoylation site of Gly2, simulating the myristoylated state of N-terminal amphipathic helix in vivo. The structural features of the nucleotide binding motifs and the switch regions prove that ARL5 will undergo the typical GDP/GTP structural cycle as other members of ARLs, which is the basis of their biological functions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15896705     DOI: 10.1016/j.bbrc.2005.04.168

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Large nucleotide-dependent conformational change in Rab28.

Authors:  Sung Haeng Lee; Kyuwon Baek; Roberto Dominguez
Journal:  FEBS Lett       Date:  2008-11-19       Impact factor: 4.124

2.  A Ras-like domain in the light intermediate chain bridges the dynein motor to a cargo-binding region.

Authors:  Courtney M Schroeder; Jonathan M L Ostrem; Nicholas T Hertz; Ronald D Vale
Journal:  Elife       Date:  2014-10-01       Impact factor: 8.140

3.  Landscape of immune infiltration in entorhinal cortex of patients with Alzheimer's disease.

Authors:  Hui Zhang; Silu Cao; Yaru Xu; Xiaoru Sun; Miaomiao Fei; Qi Jing; Xiaodong Xu; Jinxuan Tang; Bing Niu; Cheng Li
Journal:  Front Pharmacol       Date:  2022-09-28       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.